<p>Larimar Therapeutics, Inc.（纳斯达克代码：LRMR - 获取免费报告）周五股价上涨 8.2%，在 Wedbush 将该股目标价从 12.00 美元上调至 13.00 美元后。Wedbush 目前对该股的评级为跑赢大盘。Larimar Therapeutics 的股价最高达到 4.83 美元，最后交易价为 4.8350 美元。在午盘交易中，共成交 1,065,757 股，较平均交易量 4,496,090 股下降了 76%。该股此前收盘价为 4.47 美元。</p>
<p>获取 <strong>Larimar Therapeutics</strong> 的提醒：</p>
<ul>
<li>根据表现排名的最佳股票选择 AI</li>
</ul>
<p>其他一些券商最近也对 LRMR 发表了评论。Leerink Partners 在 1 月 5 日的研究报告中将 Larimar Therapeutics 的股票评级上调至 “强买入”。Weiss Ratings 在 1 月 22 日的报告中重申了对 Larimar Therapeutics 的 “卖出（d-）” 评级。花旗集团在 2 月 25 日的研究报告中将 Larimar Therapeutics 的目标价从 12.00 美元上调至 14.00 美元，并给予该公司 “买入” 评级。最后，Lifesci Capital 在 2 月 24 日的研究报告中将 Larimar Therapeutics 的评级上调至 “强买入”。两位股票研究分析师对该股给予了强买入评级，七位分析师给予了买入评级，一位分析师给予了卖出评级。根据 MarketBeat 的数据，Larimar Therapeutics 目前的共识评级为 “买入”，平均目标价为 16.43 美元。</p>
<p><strong>获取我们最新的 LRMR 股票分析</strong></p>
<h2>Larimar Therapeutics 的内部买卖</h2>
<p>在 Larimar Therapeutics 的其他新闻中，董事 James E. Flynn 在 2 月 27 日的交易中购买了 5,000,000 股该公司的股票。该股票的平均购买价格为每股 5.00 美元，总交易额为 25,000,000.00 美元。交易后，该董事在公司持有 10,622,957 股，价值 53,114,785 美元。该交易使其持股增加了 88.92%。该交易已在向 SEC 提交的文件中披露，文件可通过 SEC 网站获取。内部人士持有该公司 4.50% 的股份。</p>
<h2>机构资金流入和流出</h2>
<p>几家大型投资者最近对该公司的持仓进行了调整。Deerfield Management Company L.P.在第三季度将其在 Larimar Therapeutics 的股份增加了 44.2%。Deerfield Management Company L.P.目前持有 30,606,974 股该公司的股票，价值 98,861,000 美元，在此期间又购买了 9,375,000 股。Opaleye Management Inc.在第二季度将其在 Larimar Therapeutics 的持仓增加了 114.7%。Opaleye Management Inc.目前持有 4,110,000 股该公司的股票，价值 11,878,000 美元，在此期间又购买了 2,195,923 股。Woodline Partners LP 在第三季度将其在 Larimar Therapeutics 的持仓增加了 160.6%。Woodline Partners LP 目前持有 1,622,850 股该公司的股票，价值 5,242,000 美元，在上个季度又购买了 1,000,168 股。AIGH Capital Management LLC 在第四季度将其在 Larimar Therapeutics 的持仓增加了 100.0%。AIGH Capital Management LLC 目前持有 2,000,000 股该公司的股票，价值 7,620,000 美元，在此期间又购买了 1,000,000 股。最后，Blue Owl Capital Holdings LP 在第四季度将其在 Larimar Therapeutics 的持仓增加了 16.6%。Blue Owl Capital Holdings LP 目前持有 6,823,690 股该公司的股票，价值 25,998,000 美元，在此期间又购买了 970,650 股。91.92% 的股票由对冲基金和其他机构投资者持有。</p>
<h2>Larimar Therapeutics 股价上涨 8.4%</h2>
<p>该公司的 50 日移动平均价格为 3.93 美元，200 日移动平均价格为 3.91 美元。该股市值为 5.02 亿美元，市盈率为-2.55，贝塔值为 0.91。</p>
<p>Larimar Therapeutics（纳斯达克代码：LRMR - 获取免费报告）最后一次公布季度财报是在 3 月 23 日。该公司报告季度每股收益（EPS）为（0.73 美元），低于共识预期的（0.43 美元）0.30 美元。整体来看，分析师预计 Larimar Therapeutics, Inc.在本年度的每股收益将为-1.15 美元。</p>
<h2>关于 Larimar Therapeutics</h2>
<p>（获取免费报告）</p>
<p>Larimar Therapeutics, Inc.是一家临床阶段的生物技术公司，专注于利用其新型细胞穿透肽技术平台开发罕见疾病的治疗方案。其主要产品候选药物 CTI-1601 目前正在进行针对弗里德里希共济失调的第二阶段 OLE 临床试验，这是一种罕见的、进行性且致命的遗传疾病。Larimar Therapeutics, Inc.总部位于宾夕法尼亚州巴拉金威德。</p>
<h2>另见</h2>
<ul>
<li>五只我们更看好的股票，胜过 Larimar Therapeutics</li>
</ul>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Larimar Therapeutics 吗？</h2>
<p>在你考虑 Larimar Therapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 跟踪华尔街顶级评级和表现最佳的研究分析师及其每日推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买...而 Larimar Therapeutics 并不在名单上。</p>
<p>虽然 Larimar Therapeutics 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

LRMR

<p>Larimar Therapeutics（纳斯达克代码：LRMR）股价上涨 8.2%，在 Wedbush 将其目标价从 12.00 美元上调至 13.00 美元，并维持 “跑赢大盘” 评级后，该股交易价格为 4.83 美元，交易量显著下降。其他券商也发布了评级，普遍评级为 “买入”，平均目标价为 16.43 美元。内部交易方面，董事 James E. Flynn 购买了 500 万股。机构投资者增加了持股比例，91.92% 的股份由对冲基金持有。该公司专注于罕见疾病的治疗，其主要产品正在进行临床试验</p>

<p>Larimar Therapeutics, Inc. (NASDAQ:LRMR - Get Free Report) shares shot up 8.2% on Friday after Wedbush raised their price target on the stock from $12.00 to $13.00. Wedbush currently has an outperform rating on the stock. Larimar Therapeutics traded as high as $4.83 and last traded at $4.8350. 1,065,757 shares were traded during mid-day trading, a decline of 76% from the average session volume of 4,496,090 shares. The stock had previously closed at $4.47.</p>
<div class="lb-trans"><p>Larimar Therapeutics, Inc.（纳斯达克代码：LRMR - 获取免费报告）周五股价上涨 8.2%，在 Wedbush 将该股目标价从 12.00 美元上调至 13.00 美元后。Wedbush 目前对该股的评级为跑赢大盘。Larimar Therapeutics 的股价最高达到 4.83 美元，最后交易价为 4.8350 美元。在午盘交易中，共成交 1,065,757 股，较平均交易量 4,496,090 股下降了 76%。该股此前收盘价为 4.47 美元。</p>
</div><p>Get <strong>Larimar Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Larimar Therapeutics</strong> 的提醒：</p>
</div><ul>
<li>The Best AI for Picking Stocks, Ranked by Performance</li>
</ul>
<div class="lb-trans"><ul>
<li>根据表现排名的最佳股票选择 AI</li>
</ul>
</div><p>A number of other brokerages have also recently commented on LRMR. Leerink Partners upgraded shares of Larimar Therapeutics to a &#34;strong-buy&#34; rating in a research note on Monday, January 5th. Weiss Ratings reaffirmed a &#34;sell (d-)&#34; rating on shares of Larimar Therapeutics in a report on Thursday, January 22nd. Citigroup lifted their price target on Larimar Therapeutics from $12.00 to $14.00 and gave the company a &#34;buy&#34; rating in a research report on Wednesday, February 25th. Finally, Lifesci Capital upgraded Larimar Therapeutics to a &#34;strong-buy&#34; rating in a research note on Tuesday, February 24th. Two equities research analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Larimar Therapeutics currently has a consensus rating of &#34;Buy&#34; and an average price target of $16.43.</p>
<div class="lb-trans"><p>其他一些券商最近也对 LRMR 发表了评论。Leerink Partners 在 1 月 5 日的研究报告中将 Larimar Therapeutics 的股票评级上调至 “强买入”。Weiss Ratings 在 1 月 22 日的报告中重申了对 Larimar Therapeutics 的 “卖出（d-）” 评级。花旗集团在 2 月 25 日的研究报告中将 Larimar Therapeutics 的目标价从 12.00 美元上调至 14.00 美元，并给予该公司 “买入” 评级。最后，Lifesci Capital 在 2 月 24 日的研究报告中将 Larimar Therapeutics 的评级上调至 “强买入”。两位股票研究分析师对该股给予了强买入评级，七位分析师给予了买入评级，一位分析师给予了卖出评级。根据 MarketBeat 的数据，Larimar Therapeutics 目前的共识评级为 “买入”，平均目标价为 16.43 美元。</p>
</div><p><strong>Get Our Latest Stock Analysis on LRMR</strong></p>
<div class="lb-trans"><p><strong>获取我们最新的 LRMR 股票分析</strong></p>
</div><h2>Insider Buying and Selling at Larimar Therapeutics</h2>
<div class="lb-trans"><h2>Larimar Therapeutics 的内部买卖</h2>
</div><p>In other Larimar Therapeutics news, Director James E. Flynn purchased 5,000,000 shares of the company's stock in a transaction dated Friday, February 27th. The stock was purchased at an average price of $5.00 per share, for a total transaction of $25,000,000.00. Following the transaction, the director owned 10,622,957 shares in the company, valued at $53,114,785. The trade was a 88.92% increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders own 4.50% of the company's stock.</p>
<div class="lb-trans"><p>在 Larimar Therapeutics 的其他新闻中，董事 James E. Flynn 在 2 月 27 日的交易中购买了 5,000,000 股该公司的股票。该股票的平均购买价格为每股 5.00 美元，总交易额为 25,000,000.00 美元。交易后，该董事在公司持有 10,622,957 股，价值 53,114,785 美元。该交易使其持股增加了 88.92%。该交易已在向 SEC 提交的文件中披露，文件可通过 SEC 网站获取。内部人士持有该公司 4.50% 的股份。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入和流出</h2>
</div><p>Several large investors have recently made changes to their positions in the business. Deerfield Management Company L.P. increased its stake in shares of Larimar Therapeutics by 44.2% during the third quarter. Deerfield Management Company L.P. now owns 30,606,974 shares of the company's stock valued at $98,861,000 after buying an additional 9,375,000 shares during the period. Opaleye Management Inc. increased its position in Larimar Therapeutics by 114.7% during the 2nd quarter. Opaleye Management Inc. now owns 4,110,000 shares of the company's stock valued at $11,878,000 after purchasing an additional 2,195,923 shares during the period. Woodline Partners LP raised its holdings in Larimar Therapeutics by 160.6% in the 3rd quarter. Woodline Partners LP now owns 1,622,850 shares of the company's stock worth $5,242,000 after purchasing an additional 1,000,168 shares in the last quarter. AIGH Capital Management LLC lifted its position in shares of Larimar Therapeutics by 100.0% in the 4th quarter. AIGH Capital Management LLC now owns 2,000,000 shares of the company's stock worth $7,620,000 after purchasing an additional 1,000,000 shares during the period. Finally, Blue Owl Capital Holdings LP lifted its position in shares of Larimar Therapeutics by 16.6% in the 4th quarter. Blue Owl Capital Holdings LP now owns 6,823,690 shares of the company's stock worth $25,998,000 after purchasing an additional 970,650 shares during the period. 91.92% of the stock is owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>几家大型投资者最近对该公司的持仓进行了调整。Deerfield Management Company L.P.在第三季度将其在 Larimar Therapeutics 的股份增加了 44.2%。Deerfield Management Company L.P.目前持有 30,606,974 股该公司的股票，价值 98,861,000 美元，在此期间又购买了 9,375,000 股。Opaleye Management Inc.在第二季度将其在 Larimar Therapeutics 的持仓增加了 114.7%。Opaleye Management Inc.目前持有 4,110,000 股该公司的股票，价值 11,878,000 美元，在此期间又购买了 2,195,923 股。Woodline Partners LP 在第三季度将其在 Larimar Therapeutics 的持仓增加了 160.6%。Woodline Partners LP 目前持有 1,622,850 股该公司的股票，价值 5,242,000 美元，在上个季度又购买了 1,000,168 股。AIGH Capital Management LLC 在第四季度将其在 Larimar Therapeutics 的持仓增加了 100.0%。AIGH Capital Management LLC 目前持有 2,000,000 股该公司的股票，价值 7,620,000 美元，在此期间又购买了 1,000,000 股。最后，Blue Owl Capital Holdings LP 在第四季度将其在 Larimar Therapeutics 的持仓增加了 16.6%。Blue Owl Capital Holdings LP 目前持有 6,823,690 股该公司的股票，价值 25,998,000 美元，在此期间又购买了 970,650 股。91.92% 的股票由对冲基金和其他机构投资者持有。</p>
</div><h2>Larimar Therapeutics Trading Up 8.4%</h2>
<div class="lb-trans"><h2>Larimar Therapeutics 股价上涨 8.4%</h2>
</div><p>The business's 50 day moving average price is $3.93 and its two-hundred day moving average price is $3.91. The stock has a market cap of $502.00 million, a P/E ratio of -2.55 and a beta of 0.91.</p>
<div class="lb-trans"><p>该公司的 50 日移动平均价格为 3.93 美元，200 日移动平均价格为 3.91 美元。该股市值为 5.02 亿美元，市盈率为-2.55，贝塔值为 0.91。</p>
</div><p>Larimar Therapeutics (NASDAQ:LRMR - Get Free Report) last announced its quarterly earnings data on Monday, March 23rd. The company reported ($0.73) EPS for the quarter, missing the consensus estimate of ($0.43) by ($0.30). As a group, analysts expect that Larimar Therapeutics, Inc. will post -1.15 earnings per share for the current year.</p>
<div class="lb-trans"><p>Larimar Therapeutics（纳斯达克代码：LRMR - 获取免费报告）最后一次公布季度财报是在 3 月 23 日。该公司报告季度每股收益（EPS）为（0.73 美元），低于共识预期的（0.43 美元）0.30 美元。整体来看，分析师预计 Larimar Therapeutics, Inc.在本年度的每股收益将为-1.15 美元。</p>
</div><h2>About Larimar Therapeutics</h2>
<div class="lb-trans"><h2>关于 Larimar Therapeutics</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Larimar Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc is based in Bala Cynwyd, Pennsylvania.</p>
<div class="lb-trans"><p>Larimar Therapeutics, Inc.是一家临床阶段的生物技术公司，专注于利用其新型细胞穿透肽技术平台开发罕见疾病的治疗方案。其主要产品候选药物 CTI-1601 目前正在进行针对弗里德里希共济失调的第二阶段 OLE 临床试验，这是一种罕见的、进行性且致命的遗传疾病。Larimar Therapeutics, Inc.总部位于宾夕法尼亚州巴拉金威德。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另见</h2>
</div><ul>
<li>Five stocks we like better than Larimar Therapeutics</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 Larimar Therapeutics</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Larimar Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Larimar Therapeutics 吗？</h2>
</div><p>Before you consider Larimar Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Larimar Therapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Larimar Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 跟踪华尔街顶级评级和表现最佳的研究分析师及其每日推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买...而 Larimar Therapeutics 并不在名单上。</p>
</div><p>While Larimar Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Larimar Therapeutics 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Larimar Therapeutics（纳斯达克股票代码：LRMR）在分析师上调评级后，股价上涨了 8.2%